Please assess the completion status of the following clinical trial:

Trial Title: Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological confirmation of prostate adenocarcinoma~* Advanced prostate carcinoma.~* Previous treatment with hormones~* Levels of testosterone \< 50 ng/dL~* Good hematological, liver and kidney function~* Previous treatment with surgery or radiotherapy, at least 4 weeks since end of treatment is allowed (the patient should have been recovered from any side effects.~Exclusion Criteria:~* Previous chemotherapy (estramustine included).~* Second line hormonotherapy (oestrogens, gestagens, ketoconazole, ...included)~* Previous treatment with radiotherapy (isotopes) or previous radiotherapy over \> 25% of the marrow~* Any malignant process with a free disease interval under 5 years, exception done to non-melanoma skin cancer.~* Concomitant serious diseases~* Concomitant treatment with any other neoplassic therapy (exception done to LHRH agonists and/or biphosphonates).~* Contraindication for the treatment with estramustine.~* Previous history of pulmonary embolism, thromboembolic disease, previous treatment with anticoagulants (except aspirin), active thrombophlebitis or hypercoagulation.~* Previous history of pulmonary spillage or ascitis.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Docetaxel + Estramustine + Hydrocortisone
- 2 (Type: ACTIVE_COMPARATOR): Docetaxel + Prednisone

Based on this trial design, predict the completion outcome and termination type (if applicable).